SK30797A3 - Use of il-4 for potentiation of chemotherapeutic agents - Google Patents

Use of il-4 for potentiation of chemotherapeutic agents Download PDF

Info

Publication number
SK30797A3
SK30797A3 SK307-97A SK30797A SK30797A3 SK 30797 A3 SK30797 A3 SK 30797A3 SK 30797 A SK30797 A SK 30797A SK 30797 A3 SK30797 A3 SK 30797A3
Authority
SK
Slovakia
Prior art keywords
chemotherapeutic agents
cancer
hodgkin
patients
enhancing
Prior art date
Application number
SK307-97A
Other languages
English (en)
Slovak (sk)
Inventor
Mary E Rybak
Bertrand Coiffier
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SK30797A3 publication Critical patent/SK30797A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK307-97A 1994-09-07 1995-09-07 Use of il-4 for potentiation of chemotherapeutic agents SK30797A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30192994A 1994-09-07 1994-09-07
US08/321,504 US5716612A (en) 1994-09-07 1994-10-12 Use of IL-4 for potentiation of chemotherapeutic agents
PCT/US1995/010988 WO1996007422A1 (en) 1994-09-07 1995-09-07 Use of il-4 for potentiation of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
SK30797A3 true SK30797A3 (en) 1997-11-05

Family

ID=26972669

Family Applications (1)

Application Number Title Priority Date Filing Date
SK307-97A SK30797A3 (en) 1994-09-07 1995-09-07 Use of il-4 for potentiation of chemotherapeutic agents

Country Status (14)

Country Link
US (1) US5716612A (fi)
EP (1) EP0805688A1 (fi)
JP (1) JPH09510737A (fi)
CN (1) CN1157571A (fi)
AU (1) AU3541295A (fi)
CA (1) CA2199262A1 (fi)
CZ (1) CZ68297A3 (fi)
FI (1) FI970931A (fi)
HU (1) HUT76665A (fi)
MX (1) MX9701478A (fi)
NO (1) NO971043L (fi)
PL (1) PL319034A1 (fi)
SK (1) SK30797A3 (fi)
WO (1) WO1996007422A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
WO2002032400A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
WO2017175200A1 (en) 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
DE68916444T2 (de) * 1989-10-31 1994-11-03 Schering Corp., Kenilworth, N.J. Sekretorische e-coli-stämme.
ATE145556T1 (de) * 1990-09-06 1996-12-15 Schering Corp Verwendung von interleukin-4 zur behandlung der festen tumoren
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies
JPH05964A (ja) * 1991-06-19 1993-01-08 Tonen Corp 骨疾患治療薬及び高カルシウム血症治療薬

Also Published As

Publication number Publication date
JPH09510737A (ja) 1997-10-28
CN1157571A (zh) 1997-08-20
NO971043D0 (no) 1997-03-06
FI970931A0 (fi) 1997-03-05
MX9701478A (es) 1997-05-31
NO971043L (no) 1997-05-06
WO1996007422A1 (en) 1996-03-14
CA2199262A1 (en) 1996-03-14
PL319034A1 (en) 1997-07-21
FI970931A (fi) 1997-03-05
EP0805688A1 (en) 1997-11-12
CZ68297A3 (en) 1997-10-15
AU3541295A (en) 1996-03-27
HUT76665A (en) 1997-10-28
US5716612A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
Wing et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients
Root et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients
Rabinowitz et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support
US5437863A (en) Method of enhancing the growth of gut epithelial cells by administration of a cytokine such as interleukin II
CN1845757B (zh) 细胞因子混合物在制备由于预敏化癌症的药物中的用途和用于治疗癌症的药物组合物
HU215389B (hu) Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására
EP1608397B1 (en) S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
Rahman et al. Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts
Sredni et al. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.
SK30797A3 (en) Use of il-4 for potentiation of chemotherapeutic agents
CN1064018A (zh) 治疗细胞增殖紊乱所用组合物的制备方法
Bui et al. Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs
Tate et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects
Mitsuyasu et al. Clinical role of granulocyte-macrophage colony-stimulating factor
Davidkova et al. Endogenous production of tumor necrosis factor in normal mice orally treated with DEODAN—a preparation from Lactobacillus bulgaricus “LB51”
Kimball et al. Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole
WO2013016634A1 (en) Use of il-12 to generate endogenous erythropoietin
Troussard et al. Human recombinant granulocyte‐macrophage colony stimulating factor (hrGM‐CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: A pilot study
HUT63062A (en) Process for producing pharmaceutical compositions increasing the immune response and comprising il-4
WO2019126384A1 (en) Effective il-12 dosing regimens
Itälä et al. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections
EP0561927B1 (en) Pharmaceutical compositions for the treatment of b-cell malignancies
Gol et al. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo
Takada et al. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer
Miles et al. The use of hematopoietic hormones in HIV infection and AIDS-related malignancies